Batm Advanced Communicat... Share Discussion Threads

[baz9707] 14/3/2020 16:03

Egens Biotechnology and BATM tie up could be bearing fruit.

[baz9707] 14/3/2020 14:25

Space did you not listen to the proactive interview.
Clearly states in production.

[space_bob] 14/3/2020 14:03

From what I read, I came to the conclusion that they won't be selling kits until the end of year at least. On that basis I sold up last week. Good company, so I might get back in when this blows over, but I can see the price dropping over the next month as society loses its sh1t and then it's likely there'll be bigger bargains around.

[baz9707] 14/3/2020 13:59

Main thing is BATM already producing test kits, as per Proactive interview.
Website being updated for BATM and Adorx.
I think they are already selling to governments.

[tonytyke] 14/3/2020 13:27

That funding for mologic, indicates this is to develop a test, it's not ready now. Interestingly Peterborough FC have just ordered test kits for their squad £6000 in total and this works out to be £150 per test kit!!

[space_bob] 14/3/2020 12:56

hxxps://mologic.co.uk/mologic-awarded-c-1-million-by-uk-government-to-develop-rapid-diagnostic-test-for-covid-19/

[meijiman] 14/3/2020 12:28

Says a British company..who might it be?

[whatlp] 14/3/2020 11:26

I’m afraid the Covid-19 home testing kits discussed on channel 4 are made by a uk company called Biopanda and not BATM.

[baz9707] 14/3/2020 10:10

Updated website soon.

[baz9707] 14/3/2020 10:09

Let's see what the updated website says.

[supertag] 14/3/2020 10:08

USA needs loads of Test Kits. Come on BVC!
Happy Birthday to me.

[master rsi] 13/3/2020 23:31

Though the Share price fell to materialize into a rise, I hope it was not because is Friday the 13th, but because the DOW was losing ground as the London Market was closing, but at the end of the day, the Down finished 1,985 points higher.

Intraday chart for the DOW

[master rsi] 13/3/2020 23:09

It's still Friday the 13th

[master rsi] 13/3/2020 16:41

Everything lost at the end as the UT only wanted to pay 45p for 50K

[master rsi] 13/3/2020 10:29

Holding into the early gains though the volume is low.

[fse] 12/3/2020 22:27

BATM has a history of running against the markets. Corona Virus has created a panic situation and after a very long bull market that was enough to end the party. Regrettably I think panic will retain the upper hand until everyone is so fed up they will capitulate but only for a short while. Mass quarantine will become worse than the risk of getting the virus.
What is a big plus for BATM is that its brought what they do into focus and hopefully they can grab a share of this new market. Test kits and Agricultural waste and by product. They are well placed to do just that. IMO ;-)

Added link: Worth watching this recent interview with Zvi Marom. Link was posted previously but for those who missed it

[car1pet] 12/3/2020 21:12

Not a bad day when market down 10%

[master rsi] 12/3/2020 14:12

Another good bounce back from the early marked down the last offer is at 46p
Considering the FTSE is 500 points lower and the DOW is 2,000 in the red

[master rsi] 12/3/2020 00:04

Coronavirus winners/ Simon Thompson from IC - 10 March 2020
BATM Advanced Communications (BVC:41.5p), a provider of medical laboratory systems, cyber security and network solutions with extensive operations in Israel, has successfully developed a new diagnostics kit to detect COVID-19.

The kit has undergone testing by several central laboratories and hospitals that have now verified its ability to diagnose the virus. BATM has commenced production at its Adaltis facility in Rome and is working with academic and research institutions, mainly in Europe, to progress the product to make it at a price point suitable for large scale commercial production. Importantly, it supports all the Centers for Disease Control and Prevention (CDC) recommendations, and has received interest from customers in several countries. The kit can be used with the company’s diagnostic instruments and also with some competing diagnostic instruments.

It’s worth noting, too, that BATM holds a valuable 38 per cent stake in Ador Diagnostics, a company that is developing a new molecular diagnostic bench-top analyser that is able to probe 100 targets in a single proprietary carbon array, or 16 times more than existing products on the market. It is being targeted at screening for hospital-acquired infections such as MRSA and C. Diff, and to identify tropical infections in travellers returning home with fevers. Ador has received its first commercial order (for the identification of meningitis) from a leading Italian distributor of molecular and genomics products. It will be delivered in the second half of this year. COVID-19 is now included within the heavily patented Ador suite of testing kits, thus further enhancing its appeal.

The news adds further shine to BATM’s annual results which revealed a doubling of operating profit to US$5.3m on 3 per cent higher revenue of US$123m, buoyed by a barn storming second half that led to a substantial order backlog for 2020. The order flow has been strong since the year-end, too. BATM has announced a US$4m follow-on contract to an [undisclosed] government for additional hardware and software cyber security products.

The company has also won a US$1.3m contract for the supply and installation of its patented agri-waste treatment solution. The customer produces and distributes high quality fresh and frozen chicken throughout the Middle East, where it is based, as well as several countries in Asia. BATM won a US$4m contract award from a Taiwanese agri-food conglomerate at the end of last year, too. Demand for the solution can only increase following the outbreak of COVID-19 given that BATM’s proprietary solution enables the treatment of poultry remains onsite, and removes the environmental hazards associated with transporting them without the use of any harmful materials, chemicals or methods."
The shares have produced a total return of 129 per cent since I included them in my 2017 Bargain Shares Portfolio. I maintain my sum-of-the-parts valuation of £264m (60p a share) after factoring in BATM’s net cash of $44.8m (£34.7m); read-through valuations for the stakes in Ador (£17.2m) and Adaltis (£45m); property assets worth $16m (£12.4m); valuing BATM’s networking and cyber security division at $106m (£82m), or 20 times its 2019 operating profit of US$5.2m; and taking into account the value embedded in BATM’s partnership with Arm Holdings, and the group’s biomedical division, both of which are commercialising valuable IP. Buy. ..."